Evidence map›Paper›PMID 39289546›Full record

ArticleNPJ precision oncology2024

Mechanistic insights into lethal hyper progressive disease induced by PD-L1 inhibitor in metastatic urothelial carcinoma.

Kazuki Nishimura, Kiyoshi Takahara, Kazumasa Komura, Mitsuaki Ishida, Kensuke Hirosuna, Ryoichi Maenosono, Masahiko Ajiro, Moritoshi Sakamoto, Kengo Iwatsuki, Yuki Nakajima and 9 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kazuki Nishimura *Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Kiyoshi Takahara *Department of Urology, Fujita-Health University School of Medicine, Toyoake City, Aichi, Japan.
Kazumasa KomuraDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan. kazumasa.komura@ompu.ac.jp.
Mitsuaki IshidaDepartment of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Kensuke HirosunaDepartment of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama City, Okayama, Japan.
Ryoichi MaenosonoDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Masahiko AjiroDivision of Cancer RNA Research, National Cancer Center Research Institute, Chuo-Ku, Tokyo, Japan.
Moritoshi SakamotoDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Kengo IwatsukiDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Yuki NakajimaDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Takuya TsujinoDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Kohei TaniguchiDivision of Translational Research, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Tomohito TanakaDivision of Translational Research, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Teruo InamotoDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Yoshinobu HiroseDepartment of Pathology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.
Fumihito OnoDivision of Translational Research, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.ORCID http://orcid.org/0000-0001-7532-5262
Yoichi KondoDepartment of Anatomy and Cell Biology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Akihide YoshimiDivision of Cancer RNA Research, National Cancer Center Research Institute, Chuo-Ku, Tokyo, Japan. ayoshimi@ncc.go.jp.ORCID http://orcid.org/0000-0002-0664-7281
Haruhito AzumaDepartment of Urology, Osaka Medical and Pharmaceutical University, Takatsuki City, Osaka, Japan.

Funding

Japan Agency for Medical Research and Development (AMED) JP22am0401007Japan Agency for Medical Research and Development (AMED) JP22jm0210085MEXT | Japan Society for the Promotion of Science (JSPS) 21H03070MEXT | Japan Society for the Promotion of Science (JSPS) 21H04828
6 · The paper itself

Abstract

Hyper progressive disease (HPD) is a paradoxical phenomenon characterized by accelerated tumor growth following treatment with immune checkpoint inhibitors. However, the pathogenic causality and its predictor remain unknown. We herein report a fatal case of HPD in a 50-year-old man with metastatic bladder cancer. He had achieved a complete response (CR) through chemoradiation therapy followed by twelve cycles of chemotherapy, maintaining CR for 24 months. Three weeks after initiating maintenance use of a PD-L1 inhibitor, avelumab, a massive amount of metastases developed, leading to the patient's demise. Omics analysis, utilizing metastatic tissues obtained from an immediate autopsy, implied the contribution of M2 macrophages, TGF-β signaling, and interleukin-8 to HPD pathogenesis.

Identifiers

PMID39289546
PMCPMC11408499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.